Bavarian Nordic appoints Tarja Stenvall as CEO from October
Bavarian Nordic has named Tarja Stenvall as its new President and Chief Executive Officer, with her tenure beginning on 15 October 2026. She succeeds Paul Chaplin, whose departure from the Copenhagen-listed vaccine company was signalled earlier this year.
Stenvall brings more than two decades of senior leadership across the global pharmaceutical and vaccines industry, having held executive roles at Sanofi, AstraZeneca, and Pfizer. Most recently she served as Senior Vice President and Head of Global Franchise for diabetes and cardiovascular diseases at Sanofi, where she oversaw portfolio strategy and long-term planning for a franchise with roughly €10 billion in revenues. Earlier Sanofi roles included Senior Vice President for Key Markets in General Medicines and Vice President for Vaccines in Latin America, the latter involving what the company describes as Sanofi's largest global private-public partnership.
A commercial profile for a commercial moment
Chair of the Board Anne Louise Eberhard said the appointment followed a comprehensive search and that Stenvall brings "a proven ability to scale and lead a global life science business, combining strategic vision with deep experience from global pharma and vaccines industry." Eberhard also acknowledged Chaplin's role in transforming Bavarian Nordic from a research-focused organisation into what she described as a company that "plays an important role in securing public health worldwide."
Stenvall's background is primarily commercial rather than scientific, a profile that reflects where Bavarian Nordic currently sits strategically. The company holds a leading position in mpox and smallpox vaccines, supplying governments for public health preparedness, and operates a growing travel vaccines portfolio. The immediate priority for any incoming CEO will be sustaining and expanding government supply agreements while building a commercially viable travel health franchise that is less dependent on outbreak-driven demand.
Market context and competitive landscape
The global vaccines market continues to attract significant investment and executive attention, particularly in the wake of sustained mpox outbreaks across multiple continents and ongoing policy discussions around pandemic preparedness. Bavarian Nordic is one of a small number of companies with approved, scalable mpox vaccine capacity, giving it an unusual degree of pricing power in government tender processes. That advantage is, however, contingent on public health procurement cycles, which can be volatile.
In travel vaccines, Bavarian Nordic competes with larger players including GSK and Sanofi Pasteur, both of which have substantially greater commercial infrastructure. Stenvall's experience building franchise organisations at Sanofi, including its vaccines division in Latin America, may prove directly relevant to accelerating Bavarian Nordic's distribution reach in markets where travel vaccine penetration remains low.
The incoming executive management team will also include Henrik Juuel as CFO, Jean-Christophe May as Chief Commercial Officer, and Russell Thirsk as Chief Operating Officer.
Stenvall's appointment signals a board preference for operational scale and commercial execution at a point when Bavarian Nordic's scientific platform is largely established. Investors and public health stakeholders will be watching closely to see whether she can convert the company's preparedness franchise into a more predictable revenue base and whether travel vaccines can grow into a meaningful second pillar for the business.